There is a lot of speculation in America about when the Moderna corona vaccine will come. The Swiss firm Lonza said yesterday that the front line vaccine manufacturer in the United States could bring vaccines in 2020. Moderna CEO Stephen Bansell said the vaccine would not come before the presidential election. Moderna is not in favor of rushing for vaccination. The day may be announced at the end of November after the safety trial.
Stephen, the CEO of US pharma giant Moderna, has hinted that the vaccine may be introduced after November 25. He said the vaccine result in the three-level trial is very good. So there is no need to bring the vaccine early on an emergency basis. Detailed information will be sent to the US Food and Drug Administration (FDA) as soon as the safety trial report is completed after the final trial. “Protecting people is more important than running ahead with the vaccine,” he said.
The CEO said that preparations for mass production of the vaccine will start from the end of October. By then you will have a definite idea about the dose of the vaccine. The vaccine vial will be stored at a temperature of minus 60 degrees Celsius.
Moderna has previously said that only healthy people between the ages of 18 and 50 will have a vaccine trial. Cancer patients and HIV patients will not be vaccinated. In the revised guidelines, Moderna states that the MRNA-1263 vaccine, which uses Messenger RNA (ribonucleic acid) sequences, is also safe for HIV patients. It reveals that evidence in the safety trial. Therefore patients will be monitored with low dose injection.
The report of the first phase trial of the Moderna MRNA-1263 vaccine has come to light even before Oxford University. This vaccine is also reported to have produced antibodies in the human body. Moderna CEO Stephen Bansell said “The vaccine trial is underway in the third and final round. 30,000 people are being vaccinated. The trial is being monitored by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).”
Moderna developed the M RNA vaccine under the supervision of Anthony Fauji, director of the National Institute of Allergy and Infectious Diseases and chief health adviser to the White House. The study was carried out by scientists at the Vaccine Research Center (VRC) under NIH. Moderna also has a 10-year contract
with Lonza Group AG, one of Switzerland’s largest vaccine and pharmaceutical companies. CEO Stephen said “Many big steps have been taken in the third phase of the trial. Vaccines have been introduced into HIV patients. When this success is achieved, there will be no doubt about the effectiveness and safety of the vaccine.”